DIQTA 1.0: Drug-Induced QT Prolongation Atlas

OZANIMOD HYDROCHLORIDE

Classification:Moderate-DIQT concern

Severity Score:3.0

DRUG INTERACTIONS
Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs That may Decrease Heart Rate
ZEPOSIA has not been studied in patients taking QT prolonging drugs.
Class Ia (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) anti-arrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia. If treatment with ZEPOSIA is considered, advice from a cardiologist should be sought.
Because of the potential additive effects on heart rate, treatment with ZEPOSIA should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties [see WARNINGS AND PRECAUTIONS (5.2)]. If treatment initiation with ZEPOSIA is considered in patients on QT prolonging drugs, advice from a cardiologist should be sought.
CLINICAL PHARMACOLOGY
Pharmacodynamics
Cardiac Electrophysiology
Following a 14-day titration regimen of once daily doses of ozanimod 0.23 mg for 4 days, 0.46 mg for 3 days, 0.92 mg for 3 days, and 1.84 mg (2 times the maximum approved recommended dose) for 4 days in healthy subjects, ZEPOSIA did not prolong the QTc interval to any clinically relevant extent [see WARNINGS AND PRECAUTIONS (5.2)].

Current Drug

Other Drugs

QT Prolongation

24092

Other ADRs

38381587

Odds Ratio = N/A

ATC Code(s):

Active Ingredient:OZANIMOD HYDROCHLORIDE

Active Ingredient UNII:3UPR33JAAM

Drugbank ID:DB12612

PubChem Compound:52938427

PharmGKB:

CAS Number:1306760-87-1

Dosage Form(s):capsule; kit

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N

N/A